×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
🎬
Demo Video
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Demo Video
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Clinical: RO7126209 (Brain Shuttle AD) Phase 1/2 Trial — NCT04639050
clinical
1,406 words
KG: RO7126209 (Brain Shuttle AD) Phase 1/2 Trial — NCT04639050
Contents
RO7126209 (Brain Shuttle AD) Phase 1/2 Trial — NCT04639050
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (8)
Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli
Score: 0.67
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.77
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.75
Phase-Separated Organelle Targeting
Score: 0.73
Stress Granule Phase Separation Modulators
Score: 0.72
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.72
Blood-Brain Barrier SPM Shuttle System
Score: 0.53
Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener
Score: 0.53
Related Analyses (17)
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · completed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Show 12 more
Related Experiments (1)
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Knowledge Graph (1 edges)
RO7126209 (Brain Shuttle AD) Phase 1/2 Trial — NCT04639050
references
GFAP
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.